3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Other hematologic neoplasm
2
Tumor-Agnostic
1
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Interventions
Doxorubicin
25
Cyclophosphamide
24
pembrolizumab
20
Specimen Handling
19
Temozolomide
16
Magnetic Resonance Spectroscopy
15
Surgical Procedures, Operative
14
Radiotherapy
13
Blood Specimen Collection
13
Biopsy
13
atezolizumab
12
Gemcitabine
12
fludarabine
11
Vincristine
11
Ifosfamide
11
X-Rays
8
Trabectedin
8
Nivolumab
8
Irinotecan
8
Imatinib Mesylate
8
Drug Therapy
8
cabozantinib
7
Surveys and Questionnaires
7
Radiation
7
liposomal doxorubicin
5
abemaciclib
5
Sunitinib
5
Standard of Care
5
Radiation Dose Hypofractionation
5
Dactinomycin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
capmatinib
×
Sarcoma
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled